This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shortridge, V. D.
Right arrow Articles by Flamm, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shortridge, V. D.
Right arrow Articles by Flamm, R. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 783-786, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.783-786.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci

Virginia D. Shortridge,* Ping Zhong,{dagger} Zhensheng Cao, Jill M. Beyer, Laurel S. Almer, Nancy C. Ramer, Stella Z. Doktor, and Robert K. Flamm

Discovery and Clinical Microbiology, Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064

Received 12 February 2001/ Returned for modification 16 August 2001/ Accepted 18 November 2001

The activity of a new ketolide, ABT-773, was compared to the activity of the ketolide telithromycin (HMR-3647) against over 600 gram-positive clinical isolates, including 356 Streptococcus pneumoniae, 167 Staphylococcus aureus, and 136 Streptococcus pyogenes isolates. Macrolide-susceptible isolates as well as macrolide-resistant isolates with ribosomal methylase (Erm), macrolide efflux (Mef), and ribosomal mutations were tested using the NCCLS reference broth microdilution method. Both compounds were extremely active against macrolide-susceptible isolates, with the minimum inhibitory concentrations at which 90% of the isolates tested were inhibited (MIC90s) for susceptible streptococci and staphylococci ranging from 0.002 to 0.03 µg/ml for ABT-773 and 0.008 to 0.06 µg/ml for telithromycin. ABT-773 had increased activities against macrolide-resistant S. pneumoniae (Erm MIC90, 0.015 µg/ml; Mef MIC90, 0.12 µg/ml) compared to those of telithromycin (Erm MIC90, 0.12 µg/ml; Mef MIC90, 1 µg/ml). Both compounds were active against strains with rRNA or ribosomal protein mutations (MIC90, 0.12 µg/ml). ABT-773 was also more active against macrolide-resistant S. pyogenes (ABT-773 Erm MIC90, 0.5 µg/ml; ABT-773 Mef MIC90, 0.12 µg/ml; telithromycin Erm MIC90, >8 µg/ml; telithromycin Mef MIC90, 1.0 µg/ml). Both compounds lacked activity against constitutive macrolide-resistant Staphylococcus aureus but had good activities against inducibly resistant Staphylococcus aureus (ABT-773 MIC90, 0.06 µg/ml; telithromycin MIC90, 0.5 µg/ml). ABT-773 has superior activity against macrolide-resistant streptococci compared to that of telithromycin.

* Corresponding author. Mailing address: Dept. 47t, Bldg. AP52N, 200 Abbott Park Rd., Abbott Park, IL 60064-6217. Phone: (847) 938-1051. Fax: (847) 935-0400. E-mail: dee.shortridge{at}abbott.com.

{dagger} Present address: Givaudan Flavors Corp., Cincinnati, Ohio.

Antimicrobial Agents and Chemotherapy, March 2002, p. 783-786, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.783-786.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kouvela, E. C., Kalpaxis, D. L., Wilson, D. N., Dinos, G. P. (2009). Distinct Mode of Interaction of a Novel Ketolide Antibiotic That Displays Enhanced Antimicrobial Activity. Antimicrob. Agents Chemother. 53: 1411-1419 [Abstract] [Full Text]  
  • Robertson, G. T., Doyle, T. B., Du, Q., Duncan, L., Mdluli, K. E., Lynch, A. S. (2007). A Novel Indole Compound That Inhibits Pseudomonas aeruginosa Growth by Targeting MreB Is a Substrate for MexAB-OprM. J. Bacteriol. 189: 6870-6881 [Abstract] [Full Text]  
  • Martin, M., Quilici, S., File, T., Garau, J., Kureishi, A., Kubin, M. (2007). Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 59: 977-989 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
  • Doktor, S. Z., Shortridge, V. (2005). Differences in the DNA Sequences in the Upstream Attenuator Region of erm(A) in Clinical Isolates of Streptococcus pyogenes and Their Correlation with Macrolide/Lincosamide Resistance. Antimicrob. Agents Chemother. 49: 3070-3072 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Green, M., Allen, C., Bradley, J., Dashefsky, B., Gilsdorf, J. R., Marcon, M. J., Schutze, G. E., Smith, C., Walter, E., Martin, J. M., Edwards, K. A., Barbadora, K. A., Rumbaugh, R. M., Wald, E. R. (2005). In Vitro Activity of Telithromycin against Macrolide-Susceptible and Macrolide-Resistant Pharyngeal Isolates of Group A Streptococci in the United States. Antimicrob. Agents Chemother. 49: 2487-2489 [Abstract] [Full Text]  
  • Kasbekar, N., Acharya, P. S. (2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 62: 905-916 [Abstract] [Full Text]  
  • Doktor, S. Z., Beyer, J. M., Flamm, R. K., Shortridge, V. D. (2005). Comparison of emm Typing and Ribotyping with Three Restriction Enzymes To Characterize Clinical Isolates of Streptococcus pyogenes. J. Clin. Microbiol. 43: 150-155 [Abstract] [Full Text]  
  • Kresken, M., Henrichfreise, B., Bagel, S., Brauers, J., Wiedemann, B. (2004). High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin. Antimicrob. Agents Chemother. 48: 3193-3195 [Abstract] [Full Text]  
  • Reinert, R. R. (2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 53: 918-927 [Abstract] [Full Text]  
  • Labro, M. T., Abdelghaffar, H., Babin-Chevaye, C. (2004). Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro. Antimicrob. Agents Chemother. 48: 1096-1104 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G. (2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607 [Abstract] [Full Text]  
  • Kaieda, S., Okitsu, N., Yano, H., Hosaka, Y., Nakano, R., Okamoto, R., Takahashi, H., Inoue, M. (2003). Induction of telithromycin resistance in Streptococcus pneumoniae. J Antimicrob Chemother 52: 736-737 [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Lee, C.-M., Huang, W.-K., Wu, T.-L., Wan, J.-H., Yang, D., Shyr, J.-M., Chuang, Y.-C., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2152-2157 [Abstract] [Full Text]  
  • Morosini, M.-I., Canton, R., Loza, E., del Campo, R., Almaraz, F., Baquero, F. (2003). Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 52: 50-55 [Abstract] [Full Text]  
  • Garcia, I., Pascual, A., Ballesta, S., del Castillo, C., Perea, E. J. (2003). Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. J Antimicrob Chemother 52: 24-28 [Abstract] [Full Text]  
  • Conejo, M. d. C., Martinez-Martinez, L., Pascual, A., Suarez, A. I., Perea, E. J. (2003). Activities of ABT-773 against Listeria monocytogenes and Coryneform Bacteria of Clinical Interest. Antimicrob. Agents Chemother. 47: 1403-1406 [Abstract] [Full Text]  
  • Hamilton-Miller, J. M. T., Shah, S. (2002). Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes. J Antimicrob Chemother 50: 907-913 [Abstract] [Full Text]  
  • Leclercq, R., Courvalin, P. (2002). Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 2727-2734 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»